我要投票 德维喜DOVC在其他行业中的票数:412
· 外 推 电 报 ·
2025-08-04 03:17:09 星期一

【德维喜DOVC是哪个国家的品牌?】

德维喜DOVC是什么牌子?「德维喜DOVC」是 东北制药集团股份有限公司 旗下著名品牌。该品牌发源于辽宁省沈阳市,由创始人魏海军在1993-06-10期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力德维喜DOVC品牌出海!将品牌入驻外推网,定制德维喜DOVC品牌推广信息,可以显著提高德维喜DOVC产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

创始于1993年,知名维生素品牌,覆盖医药研发、制造、分销全产业链条,以化学原料药为主的大型综合性制药企业


东北制药集团股份有限公司(简称“东北制药”,股票代码:000597),是辽宁方大集团实业有限公司(简称“方大集团”)旗下上市公司。公司前身为东北制药总厂,始建于1946年,曾援建全国19省市52家医药企业,向外输送干部1300多人。

目前,东北制药拥有化学原料药、化学制剂、医药商业、医药工程、生物医药等主要业务板块,覆盖医药研发、制造、分销全产业链条,员工队伍9300余人,总资产120亿元。公司主要生产维生素系列药品、抗感染系统用药、妇产科系统用药、消化系统用药、泌尿系统用药、抗病毒系列用药、心脑血管系列用药、镇痛镇咳系列用药、生物诊断系列、大健康领域系列等十大系列精品,400多种化学原料药、医药中间体和制剂产品,主导产品远销100多个国家和地区。

公司拥有强大的产品制造体系。制剂生产基地占地18万平方米,拥有生产线30余条,年产能100亿片(支、丸、粒、枚、瓶)。原料药生产基地占地91万平方米,是国家大宗原料药和医药中间体智能制造示范工厂,主要产品包括维生素C及系列、左旋肉碱系列、磷霉素系列、吡拉西坦、卡前列甲酯、金刚烷胺、硫糖铝、黄连素、氯霉素等,并向下游东北制药制剂产业链延伸,形成难以复制的综合竞争优势。

东北制药不仅是中国重要的药品生产与出口基地,还设有药物研究院、工程设计公司、装备制造安装公司、国际贸易公司、计量检测公司、危化品运输公司等各独立业务公司。

东北制药医药商业业务网络覆盖辽宁全部地级市县,并向东北三省延伸,东北大药房拥有百余家连锁店,医药电商业务实现线上线下一体化,商业模式创新持续推进。


英文翻译:Founded in 1993, it is a well-known vitamin brand, covering the whole industrial chain of pharmaceutical research and development, manufacturing and distribution. Northeast Pharmaceutical Group Co., Ltd., a large comprehensive pharmaceutical enterprise mainly engaged in chemical APIs (hereinafter referred to as "Northeast Pharmaceutical", stock code: 000597), is a listed company under Liaoning Fangda Group Industry Co., Ltd. (hereinafter referred to as "Fangda group"). The company, formerly known as the Northeast Pharmaceutical General Factory, was founded in 1946. It has assisted in the construction of 52 pharmaceutical enterprises in 19 provinces and cities across the country, and has sent more than 1300 cadres. At present, Northeast Pharmaceutical has major business sectors such as chemical APIs, chemicals, pharmaceutical commerce, pharmaceutical engineering, biomedicine, covering the whole industrial chain of pharmaceutical research and development, manufacturing, distribution, with more than 9300 employees and a total asset of 12 billion yuan. The company mainly produces ten series of high-quality products, including vitamin series, anti infection system medicine, gynecology and obstetrics system medicine, digestive system medicine, urinary system medicine, anti-virus series medicine, cardiovascular and cerebrovascular series medicine, analgesia and antitussive series medicine, biological diagnosis series, large health field series, more than 400 kinds of chemical APIs, pharmaceutical intermediates and preparation products, leading products It is exported to more than 100 countries and regions. The company has a strong product manufacturing system. The preparation production base covers an area of 180000 square meters, with more than 30 production lines and an annual production capacity of 10 billion tablets (pills, granules, tablets, bottles). The API production base covers an area of 910000 square meters. It is a national bulk API and pharmaceutical intermediate intelligent manufacturing demonstration factory. Its main products include vitamin C and series, L-carnitine series, fosfomycin series, piracetam, carboprost methyl ester, amantadine, sucralfate, berberine, chloramphenicol, etc. and it extends to the downstream Northeast Pharmaceutical industry chain, forming a hard to replicate Comprehensive competitive advantage. Northeast Pharmaceutical is not only an important pharmaceutical production and export base in China, but also has independent business companies such as pharmaceutical research institute, engineering design company, equipment manufacturing and installation company, international trade company, measurement and testing company, dangerous chemicals transportation company, etc. The Northeast Pharmaceutical business network covers all prefecture level cities and counties in Liaoning, and extends to three provinces in Northeast China. The Northeast pharmacy has more than 100 chain stores. The online and offline integration of pharmaceutical e-commerce business is realized, and the innovation of business model is continuously promoted.

本文链接: https://www.waitui.com/brand/aa403ad85.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

中信证券:目前重点关注的依然聚焦在AI、创新药、资源、恒科以及科创板

中信证券研报称,行情的定位决定了主导资金的行为,资金的行为决定了上涨的行业结构及模式。历史上增量流动性驱动的行情中,领涨行业大都是持续集中,而不是高切低轮动;背后的本质是资金对效率的追逐,更倾向于高共识品种,而非在低位品种里“蹲变化”。7月的行情演绎也验证了这一点,行业逐步向趋势性品种聚焦,而高切低模式效率偏低;近期增量流动性边际上有所放缓,行情需要降温才能行稳致远。目前我们重点关注的依然聚焦在AI、创新药、资源、恒科以及科创板。

2小时前

芯导科技:拟4.03亿元购买吉瞬科技100%股权、瞬雷科技17.15%的股权 预计构成重大资产重组

8月3日,芯导科技(688230.SH)公告称,公司拟向盛锋、李晖、黄松、王青松、瞬雷优才发行可转换公司债券及支付现金,购买吉瞬科技100%股权、瞬雷科技17.15%的股权,从而直接及间接持有瞬雷科技100%股权,实现对瞬雷科技的100%控制,交易价格暂定为4.03亿元,本次交易预计构成重大资产重组。瞬雷科技主要从事功率器件的研发、生产和销售;吉瞬科技直接持有瞬雷科技82.85%的股权,仅为瞬雷科技持股主体。

2小时前

过去七天,广东新增2892例基孔肯雅热本地病例

据广东省疾控局消息,2025年7月27日0时至8月2日24时,广东全省新增报告2892例基孔肯雅热本地病例,未报告重症和死亡病例。病例分布在佛山2770例,广州65例,东莞、中山各11例,深圳、江门、肇庆各6例,梅州5例,珠海、惠州各4例,潮州2例,阳江、云浮各1例。

2小时前

银河证券:8月预计市场维持在震荡偏高中枢运行 关注结构性配置机会

8月3日,银河证券研报表示,近期市场行情呈现积极态势,上证指数多次创下年内新高。本轮行情受到流动性和市场预期双重驱动,融资余额自6月底以来持续上行,重返1.9万亿元上方。同时,股市上扬表现带动市场赚钱效应扩散,形成正向反馈。后续关注市场在关键点位附近的支撑力度,8月预计市场维持在震荡偏高中枢运行,关注结构性配置机会。

2小时前

吴声“新物种爆炸2025”:AI场景革命正在让商业开启哲学生活方式周期

8月3日,“新物种爆炸·吴声商业方法发布2025”在京举行。场景实验室创始人、场景方法论提出者吴声表示:AI场景革命正在让商业开启哲学生活方式周期,关键是在每个具体场景重建意义坐标。大会还发布了新物种爆炸2025“意义重建”的八个预测,包括算法休假的AI伦理、从跨境支付到加密生活等。

2小时前

本页详细列出关于德维喜DOVC的品牌信息,含品牌所属公司介绍,德维喜DOVC所处行业的品牌地位及优势。
咨询